REPH stock: buy or sell?
May 21st, 2019
Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States.
Should I buy REPH stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with Recro Pharma stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Recro Pharma stock a buy?
Financial institutions and banks publish stock ratings everyday.At Stocks2.com, we collected 3 ratings published for REPH stock in the last 30 days.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-1-31||Janney Montgomery Scott||Buy||Buy|
REPH stock analysis
Shares of Recro Pharma stepped up a good 1.56% and closed at $9.13.
Recro Pharma stepped up a good 1.56% and closed at $9.13. Since last April when REPH stock price broke up the SMA200d line, it gained $2.61 (40.03%). Since last January when SMA100d and SMA200d crossed up, REPH price gained $1.23 per share (15.57%). From a daily perspective, REPH is in a short term uptrend after plotting its last bottom ($8.50, on May/9) higher than the previous bottom, and its last top ($9.58, on Wednesday) also over the previous top. Now trading in between its last bottom and last top REPH might consolidate in a plain range, waiting to break out over $9.58 or down under $8.50.
Recro Pharma inched a beatiful 1.56% this week. Late April REPH boosted a superb 5.11% in just one week.
Recro Pharma is in a clear downtrend, marking successive falling peaks and bottoms. Now is trading in between the - range. There is an opportunity to rebound and reverse this situation if price can hold above the level. Since price and SMA40w lines crossed up early April, REPH climbed $3.27 (55.80%). By mid January, SMA20w and SMA40w crossed up triggering a rise of 16.75%.
REPH stock price history
REPH IPO was on March 7th, 2014 at $8.53 per share1. Since then, REPH stock surged a 7.00%, with a yearly average of 1.40%. If you had invested right after REPH's IPO a $1,000 in REPH stock in 2014, it would worth $70.00 today.
1: Adjusted price after possible price splits or reverse-splits.
REPH stock historical price chart
REPH stock reached 52-week highs at $13.05, and all-time highs 2015-07-17 with a price of 18.3.
REPH stock price target is $9.80Nobody can reliably foresee how stock prices may evolve in the future. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we found 3 price forecasts for Recro Pharma stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-1-31||Janney Montgomery Scott||Reiterates||n/a||$13.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareRecro Pharma disappointed analysts on February when it posted an Earnings per Share (EPS) of $-0.58 when the analysts' forecast was $-0.74.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual sales report draw a pretty good growth of 7.67% to $77.35 M dollars. When comparing 2018 vs 2017, nevertheless, profit margin (that is, the net income divided by revenues) collapsed a -33.36% to -103.07%.
|2015||$52 M||-||$3.03 M5.8%||-|
|2016||$69 M||33.46%||$-30.21 M-43.6%||-1,095.88%|
|2017||$72 M||3.60%||$-50.08 M-69.7%||65.80%|
|2018||$77 M||7.67%||$-79.72 M-103.1%||59.19%|
Quarterly financial resultsRecro Pharma posted $17.78 million in sales for 2018-Q4, a -2.73% decline compared to previous quarter. Reported quarter earnings marked $-41.30 M with a profit margin of -232.23%. Profit margin plunged a -159.72% compared to previous quarter when profit margin was -72.50%. When comparing turnover to same quarter last year, Recro Pharma sales marked a fateful decrease and fell a -6.62%. Looking back to recent quarterly results, Recro Pharma posted 2 negative quarters in a row.
|2017-Q1||$19 M||-||$-8.09 M-43.2%||-|
|2017-Q2||$17 M||-9.66%||$-8.86 M-52.3%||9.52%|
|2017-Q3||$17 M||1.09%||$-9.06 M-52.9%||2.20%|
|2017-Q4||$19 M||11.28%||$-24.08 M-126.5%||165.96%|
|2018-Q1||$20 M||2.61%||$-12.46 M-63.7%||-48.28%|
|2018-Q2||$22 M||11.24%||$-12.72 M-58.5%||2.09%|
|2018-Q3||$18 M||-15.90%||$-13.26 M-72.5%||4.25%|
|2018-Q4||$18 M||-2.73%||$-41.30 M-232.2%||211.53%|
Recro Pharma ownershipWhen you are planning to buy shares of a stock, it's always worth to review its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Recro Pharma, 6.09% of all outstanding shares are owned by its staff.
In case of Recro Pharma stock, 70.09% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for REPH stock account 0.00%, no big difference from last month.
For a better context understanding, the following table shows ownership data compared to other related stocks:
|Market cap||$202.5 M||$225.7 M||$401.2 M||$755.3 M||$118.5 M|
|Total shares||22.2 M||78.9 M||87.4 M||39.8 M||162.4 M|
|Float shares||14.4 M||77.7 M||59.9 M||35.1 M||155.9 M|
|- Institutional holdings (%)||70.1%||19.7%||58.8%||62.4%||46.1%|
|- Insider holdings (%)||6.1%||11.6%||6.0%||2.9%||4.0%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Tuesday, May 21st, 2019|
|Day range||$9.00 - $9.24|
|Average true range||$0.40|
|50d mov avg||$8.37|
|100d mov avg||$8.30|
|200d mov avg||$7.62|
Recro Pharma performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We compared Recro Pharma against AcelRx Pharmaceuticals, BioDelivery Sciences International, Cara Therapeutics, DURECT, Flexion Therapeutics, Insys Therapeutics, and Pacira Pharmaceuticals in the following table: